Skip to main content
. 2021 Jun 26;13(7):968. doi: 10.3390/pharmaceutics13070968

Figure 9.

Figure 9

The effect of PtPz4, PtPz6, cisPt, and anti-MUC1 on anti-apoptotic Bcl-xL mRNA, Bcl-xL protein (A), and Bcl-2 mRNA (B) expressions. The cells were incubated for 24 h with PtPz4 (10 μM), PtPz6 (10 μM), cisPt (10 μM), anti-MUC1 (5 μg/mL), PtPz4 + anti-MUC1 (10 μM + 5 μg/mL), PtPz6 + anti-MUC1 (10 μM + 5 μg/mL), and cisPt + anti-MUC1 (10 μM + 5 μg/mL). mRNAs were assessed by RT-PCR. The result is presented as a relative fold change in mRNA gene expression in comparison of gene in control (where expression was set at 1) ± SD are the mean of triplicate cultures. ** p < 0.01; *** p < 0.001. The expression of Bcl-xL protein in cell lysates was determined by Western blotting. The intensities of the bands were quantified by densitometric analysis. Data represent the mean ± SD of the relative expression levels (from three assays) normalized to β-actin. * p < 0.05; ** p < 0.01.